The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods

Author:

Zdrazil Barbara1ORCID,Felix Eloy1,Hunter Fiona1,Manners Emma J1,Blackshaw James1,Corbett Sybilla1,de Veij Marleen1,Ioannidis Harris1,Lopez David Mendez1,Mosquera Juan F1,Magarinos Maria Paula1,Bosc Nicolas1,Arcila Ricardo1,Kizilören Tevfik1,Gaulton Anna1,Bento A Patrícia1,Adasme Melissa F1,Monecke Peter2,Landrum Gregory A3,Leach Andrew R1

Affiliation:

1. European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI) , Wellcome Genome Campus , Hinxton , Cambridgeshire CB10 1SD , UK

2. Sanofi, R&D, Preclinical Safety , Industriepark Höchst , 65926 Frankfurt am Main , Germany

3. Department of Chemistry and Applied Biosciences , ETH Zürich , 8093 Zürich , Switzerland

Abstract

Abstract ChEMBL (https://www.ebi.ac.uk/chembl/) is a manually curated, high-quality, large-scale, open, FAIR and Global Core Biodata Resource of bioactive molecules with drug-like properties, previously described in the 2012, 2014, 2017 and 2019 Nucleic Acids Research Database Issues. Since its introduction in 2009, ChEMBL’s content has changed dramatically in size and diversity of data types. Through incorporation of multiple new datasets from depositors since the 2019 update, ChEMBL now contains slightly more bioactivity data from deposited data vs data extracted from literature. In collaboration with the EUbOPEN consortium, chemical probe data is now regularly deposited into ChEMBL. Release 27 made curated data available for compounds screened for potential anti-SARS-CoV-2 activity from several large-scale drug repurposing screens. In addition, new patent bioactivity data have been added to the latest ChEMBL releases, and various new features have been incorporated, including a Natural Product likeness score, updated flags for Natural Products, a new flag for Chemical Probes, and the initial annotation of the action type for ∼270 000 bioactivity measurements.

Funder

Wellcome Trust

Member States of the European Molecular Biology Laboratory

US National Institutes of Health

University of New Mexico

European Bioinformatics Institute

University of Miami

Innovative Medicines Initiative 2 Joint Undertaking

Publisher

Oxford University Press (OUP)

Subject

Genetics

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3